Not Yet Recruiting NA INTERVENTIONAL 2-arm
NCT07422103
PAN-CLO-BU (PANcreas-CLOstridium-BUtyricum) (PAN-CLO-BU)
Supplementation With Clostridium Butyricum CBM588 in Patients Undergoing Pancreaticoduodenectomy for Periampullary Neoplasms: A Prospective Randomized Double-Blind Study
Sponsor: Casa di Cura Dott. Pederzoli
Conditions
CBM588 Clostridium Butyricum Miyairi Gastrointestinal Symptoms Pancreatic Cancer Pancreatic Diseases Pancreatoduodenectomy
Interventions
Clostridium butyricum CBM588 Strain Placebo
Updated 1 time since 2026 Last updated: Feb 12, 2026 Started: Mar 15, 2026 Primary completion: Nov 30, 2028 Completion: Nov 30, 2030
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A NA clinical study on CBM588 and Clostridium Butyricum Miyairi, this trial is actively recruiting participants. The trial is conducted by Casa di Cura Dott. Pederzoli and has accumulated 1 data snapshot since 2026. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
1 version recorded Not Yet Recruiting — NA
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Casa di Cura Dott. Pederzoli
- PharmExtracta S.p.A.
Data source: Casa di Cura Dott. Pederzoli
For direct contact, visit the study record on ClinicalTrials.gov .